investerare
Med en snabbt växande verksamhet i Europa och planer på en framtida lansering i USA är Sedana Medical väl positionerat för framtiden.
Vi är på god väg mot vår vision att göra inhalationssedering till en standardbehandling inom intensivvården.
- Mikael Haag
- CFO och chef för Investor Relations
- ir@sedanamedical.com
Aktie
Pressmeddelanden
2026
2026-08-31 07:30
Sedana Medical announces PDUFA target action date for its New Drug Application in the U.S.
Sedana Medical AB (publ) today announced that the U.S. Food and Drug Administration (FDA) has set April 16, 2027 as the target action date under the Prescription...
2026-08-19 07:30
Sedana Medical announces FDA acceptance for review of its New Drug Application in the U.S.
Sedana Medical AB (publ) today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of the company's New Drug Application...
2026-07-17 07:00
Sedana Medical AB’s Interim report January-June 2026
NDA submission and improved EBITDA Second quarter 2026 January-June 2026 CEO comments NDA submission and improved EBITDA We submitted our New Drug Application...
Finansiella rapporter
Finansiell kalender
Senaste presentationen
No presentations found.